Psoriasis can increase skin infection risk due to effects from the condition and its treatments. Learn about potential infections, symptoms, and preventive measures.

Guselkumab achieved clear or almost clear skin in 74.2% of patients with moderate plaque psoriasis, compared to 12.4% on placebo. The VISIBLE study showed rapid and significant clearance of scalp ...

Guselkumab demonstrated strong efficacy in treating moderate to severe scalp psoriasis, especially in individuals with skin of color, achieving nearly 70% complete scalp clearance by week 48. The ...

Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time.

Takeda’s zasocitinib has shown strong rates of skin clearance, as well as other benefits, in new study results regarding ...

Even as the prevalence of psoriasis increases around the world, with the highest proportions found in white populations, there is apparently a greater burden of disease among populations with skin of ...

Please provide your email address to receive an email when new articles are posted on . Low body surface area psoriasis in sensitive or highly visible areas is often prescribed only topical ...

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated ...

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...